IL145898A0 - Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit - Google Patents

Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Info

Publication number
IL145898A0
IL145898A0 IL14589800A IL14589800A IL145898A0 IL 145898 A0 IL145898 A0 IL 145898A0 IL 14589800 A IL14589800 A IL 14589800A IL 14589800 A IL14589800 A IL 14589800A IL 145898 A0 IL145898 A0 IL 145898A0
Authority
IL
Israel
Prior art keywords
fibrosis
subunit
antagonist
treatment
integrin alpha
Prior art date
Application number
IL14589800A
Other languages
English (en)
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of IL145898A0 publication Critical patent/IL145898A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14589800A 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit IL145898A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13084799P 1999-04-22 1999-04-22
US13721499P 1999-06-01 1999-06-01
PCT/US2000/010781 WO2000064474A1 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit

Publications (1)

Publication Number Publication Date
IL145898A0 true IL145898A0 (en) 2002-07-25

Family

ID=26828876

Family Applications (5)

Application Number Title Priority Date Filing Date
IL14589800A IL145898A0 (en) 1999-04-22 2000-04-21 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
IL145898A IL145898A (en) 1999-04-22 2001-10-11 Antagonist of Integrine's Alpha 4 subunit for the treatment of leprosy
IL182908A IL182908A (en) 1999-04-22 2007-05-01 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
IL206829A IL206829A (en) 1999-04-22 2010-07-06 Use of an antibody-containing homologue to prepare leukocyte-induced rise in bronchoalveolar fluid-related specimen
IL206830A IL206830A (en) 1999-04-22 2010-07-06 Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL145898A IL145898A (en) 1999-04-22 2001-10-11 Antagonist of Integrine's Alpha 4 subunit for the treatment of leprosy
IL182908A IL182908A (en) 1999-04-22 2007-05-01 Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
IL206829A IL206829A (en) 1999-04-22 2010-07-06 Use of an antibody-containing homologue to prepare leukocyte-induced rise in bronchoalveolar fluid-related specimen
IL206830A IL206830A (en) 1999-04-22 2010-07-06 Use of an integrin-containing antagonist of the alpha 1 subunit - of the integrin to prepare a drug for the treatment of osteoporosis

Country Status (31)

Country Link
US (3) US6652856B2 (ja)
EP (1) EP1173201B1 (ja)
JP (3) JP5483515B2 (ja)
KR (3) KR100746522B1 (ja)
CN (3) CN1332714C (ja)
AT (1) ATE298249T1 (ja)
AU (1) AU783054B2 (ja)
BG (2) BG65578B1 (ja)
BR (1) BR0010669A (ja)
CA (1) CA2370814C (ja)
CY (1) CY1106046T1 (ja)
CZ (1) CZ301636B6 (ja)
DE (1) DE60020955T2 (ja)
DK (1) DK1173201T3 (ja)
EA (1) EA006681B1 (ja)
EE (1) EE05662B1 (ja)
ES (1) ES2243259T3 (ja)
GE (1) GEP20063844B (ja)
HK (2) HK1041452B (ja)
HU (1) HU226383B1 (ja)
IL (5) IL145898A0 (ja)
IS (1) IS2259B (ja)
MX (1) MXPA01010612A (ja)
NO (1) NO330221B1 (ja)
NZ (2) NZ541431A (ja)
PL (1) PL198975B1 (ja)
PT (1) PT1173201E (ja)
RS (2) RS50086B (ja)
SK (1) SK287328B6 (ja)
TR (1) TR200200027T2 (ja)
WO (1) WO2000064474A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541431A (en) * 1999-04-22 2008-01-31 Biogen Idec Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
UA73300C2 (en) * 1999-06-01 2005-07-15 Biogen Inc Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis
BR0011250A (pt) * 1999-06-01 2002-03-05 Biogen Inc Anticorpo monoclonal de bloqueio a vla-1 e seu uso para o tratamento de distúrbios inflamatórios
AU780358B2 (en) * 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
WO2001070210A2 (en) * 2000-03-17 2001-09-27 Avocet Polymer Technologies, Inc. Methods for improving size and appearance of a wound
AU2002225878A1 (en) * 2000-11-02 2002-05-15 Smith Kline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
AU2002258778C1 (en) 2001-04-13 2008-12-04 Biogen Ma Inc. Antibodies to VLA-1
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050053664A1 (en) * 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP3412686A1 (en) * 2003-10-17 2018-12-12 AlJamal-Naylor, Rehab Tissue repair by modulation of beta-1 integrin biological function
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2006017417A2 (en) * 2004-08-02 2006-02-16 Pro-Pharmaceuticals, Inc. Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
PT2034830E (pt) * 2006-05-25 2014-10-14 Biogen Idec Inc Anticorpos anti-vla-1 para o tratamento de acidentes vasculares cerebrais
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
AU2013221635B2 (en) 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
EP2832368B1 (en) * 2012-03-28 2021-11-10 Hiroshima University Fibrosis suppression by inhibiting integrin alpha8beta1 function
WO2014130648A1 (en) 2013-02-20 2014-08-28 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
JPH07506091A (ja) 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
CA2182013C (en) * 1994-01-25 2007-07-17 Mary M. Bendig Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
PT759302E (pt) * 1994-04-26 2001-01-31 Akzo Nobel Nv Farmaco para o tratamento da artrite reumatoide
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0827742A1 (en) * 1996-09-04 1998-03-11 Vrije Universiteit Brussel Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
JPH10330268A (ja) * 1997-05-26 1998-12-15 Kureha Chem Ind Co Ltd ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤
ES2311131T3 (es) * 1997-08-08 2009-02-01 The Regents Of The University Of California Tratamiento de la fibrosis hepatico con anticuerpos contra la integrina alfa-v-beta6.
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
NZ541431A (en) * 1999-04-22 2008-01-31 Biogen Idec Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑

Also Published As

Publication number Publication date
US20050281818A1 (en) 2005-12-22
YU74901A (sh) 2004-07-15
HUP0201015A3 (en) 2004-12-28
US20020182213A1 (en) 2002-12-05
EA006681B1 (ru) 2006-02-24
IL206830A (en) 2013-06-27
GEP20063844B (en) 2006-06-12
CN1596979A (zh) 2005-03-23
SK287328B6 (sk) 2010-07-07
US20040037827A1 (en) 2004-02-26
BG66149B1 (bg) 2011-08-31
CN1356911A (zh) 2002-07-03
CZ301636B6 (cs) 2010-05-12
IL206830A0 (en) 2010-12-30
JP2002542300A (ja) 2002-12-10
BG106118A (en) 2002-05-31
RS20080471A (en) 2010-12-31
BR0010669A (pt) 2002-02-19
CZ20013754A3 (cs) 2002-07-17
HK1041452A1 (en) 2002-07-12
CN1332714C (zh) 2007-08-22
HUP0201015A2 (hu) 2002-07-29
KR100746522B1 (ko) 2007-08-07
WO2000064474A8 (en) 2001-04-05
RS50086B (sr) 2009-01-22
IL182908A0 (en) 2007-08-19
JP2014065747A (ja) 2014-04-17
PT1173201E (pt) 2005-08-31
EE200100549A (et) 2002-12-16
EP1173201A1 (en) 2002-01-23
US6652856B2 (en) 2003-11-25
HU226383B1 (hu) 2008-10-28
PL198975B1 (pl) 2008-08-29
BG65578B1 (bg) 2009-01-30
JP5483515B2 (ja) 2014-05-07
IL145898A (en) 2007-07-24
NO20015122L (no) 2001-12-21
HK1076379A1 (en) 2006-01-20
MXPA01010612A (es) 2003-09-04
KR100837715B1 (ko) 2008-06-13
CY1106046T1 (el) 2011-04-06
CN100360183C (zh) 2008-01-09
PL351916A1 (en) 2003-06-30
AU783054B2 (en) 2005-09-22
DE60020955T2 (de) 2006-05-11
IS6105A (is) 2001-10-11
AU4480000A (en) 2000-11-10
NO330221B1 (no) 2011-03-07
IL182908A (en) 2010-11-30
CA2370814C (en) 2010-07-06
KR20070050979A (ko) 2007-05-16
IL206829A (en) 2013-06-27
IL206829A0 (en) 2010-12-30
SK15202001A3 (sk) 2002-09-10
CN1679935A (zh) 2005-10-12
NO20015122D0 (no) 2001-10-19
HK1041452B (zh) 2005-10-14
ES2243259T3 (es) 2005-12-01
CN1191860C (zh) 2005-03-09
WO2000064474A1 (en) 2000-11-02
DK1173201T3 (da) 2005-09-12
EP1173201B1 (en) 2005-06-22
JP2007182453A (ja) 2007-07-19
EE05662B1 (et) 2013-06-17
KR20020000221A (ko) 2002-01-05
ATE298249T1 (de) 2005-07-15
BG110115A (en) 2008-12-30
NZ541431A (en) 2008-01-31
TR200200027T2 (tr) 2002-07-22
IS2259B (is) 2007-06-15
EA200101116A1 (ru) 2002-04-25
NZ515053A (en) 2004-02-27
KR20070102760A (ko) 2007-10-19
CA2370814A1 (en) 2000-11-02
DE60020955D1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
IL206829A0 (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
HK1055250A1 (en) Stimulation of bone growth with thrombin peptide derivatives
HUP0202776A2 (hu) (+)-Tramadol, O-demetil-tramadol, (+)-O-demetil-tramadol, O-demetil-N-mono-demetil-tramadol, illetve (+)-O-demetil-N-mono-demetil-tramadol felhasználása vizeletinkontinencia kezelésére alkalmas gyógyszerkészítmény előállítására
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
BR0108865A (pt) Métodos de tratamento do câncer e da dor a ele associada usando antagonistas de endotelina
NZ318272A (en) Glucocorticoid enhancement of gene expression
EP1666063A3 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
AP2000002002A0 (en) Method of treatment.
IL126158A0 (en) Method for treating substance abuse
NZ329403A (en) Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed